Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.
The briefing underscores Lantern Pharma’s ongoing efforts to leverage artificial intelligence to accelerate oncology drug development. The company’s proprietary AI and machine learning platform, RADR, utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to address challenges in oncology drug development. Lantern reports that its newly developed drug programs have advanced from initial AI insights to first-in-human clinical trials in 2–3 years at a cost of approximately $1.0–2.5 million per program.
Lantern’s pipeline includes a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials, as well as an antibody-drug conjugate program. The company has also established Starlight Therapeutics, a wholly-owned subsidiary focused on CNS and brain cancers. The combined annual market potential for Lantern’s AI-driven pipeline is estimated to exceed $15 billion USD.
The live demonstration of withZeta.ai is expected to provide investors with a clearer understanding of how the platform’s multi-agentic AI capabilities could streamline drug discovery and clinical trial design for rare cancers. The event will be accessible via webcast, and more details are available in the full press release at https://ibn.fm/UXTr3.
For ongoing updates, investors can visit the company’s newsroom at https://ibn.fm/LTRN.
